Monthly Archives: March 2016

Avraham Pharmaceuticals Ltd.  has closed an investment round of approximately $4.0 million. Investors in the round include Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum’s biotech holdings company, the Technion Research and Development Foundation Ltd. (TRDF)...

BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD), a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of food into the lungs,...

Enzymotec announced that InCogTM, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study. The study evaluated the effects of InCogTM in a term and preterm piglet model relevant for...

Can-Fite has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company’s lead compound CF101 in the treatment of rheumatoid arthritis following a pre-submission meeting with the EMA. The global trial is expected to commence in either the second...

Israeli big data and intensive care analytics startup Intensix has signed an agreement with Mayo Clinic in the US to commence a study of early predictions of life-threatening complications in a critical care setting. The study will focus on the feasibility of using the Intensix platform to predict patient deterioration...

An Israeli pharmaceutical firm could be the next big producer of erectile dysfunction treatments. Petah Tikvah-based Can-Fite announced Tuesday that the US Patent and Trademark Office (one of the last stages before the actual granting of a patent) issued a Notice of Allowance for the company’s “A3 Adenosine Receptor Allosteric...

Your preschooler wakes up with an earache and fever. You tell your boss you’ll be late to work, wangle a pediatrician appointment, bundle up the sick kid, sit in a waiting room full of other sick kids, spend five minutes with the doctor, and leave with a prescription and/or orders...

The Trendlines Group has entered into a definitive collaboration framework agreement with a major multinational medical corporation headquartered in Japan. This research partnership will see the firms mutually identify specific clinical opportunities. As part of the terms of the agreement, Trendlines Labs will develop innovative medical device products for manufacturing...

WIth more than 300 employees at four sites throughout Israel, Merck KgaA, a multifaceted chemical and technology company, has quietly emerged as one of the major multinational firms with a significant presence in Israel. The company announced this week that it was furthering its stake in Israeli tech by signing...

Six pediatric medical device innovations that address a significant yet unmet pediatric need were awarded a total of $250,000 in grant money at the third annual National Capital Consortium for Pediatric Device Innovation (NCC-PDI) Competition. ApiFix was awarded a $25,000 grant for its minimally invasive correction system for patients with a spinal...